ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average – Time to Sell?

ImmuCell Co. (NASDAQ:ICCC)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.23 and traded as high as $5.17. ImmuCell shares last traded at $5.23, with a volume of 1,384 shares traded.

ImmuCell Stock Performance

The stock has a market cap of $46.59 million, a P/E ratio of -10.46 and a beta of 0.54. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 3.11. The firm’s 50 day moving average is $5.09 and its 200 day moving average is $4.23.

Institutional Trading of ImmuCell

A number of institutional investors have recently made changes to their positions in ICCC. Mesirow Financial Investment Management Inc. raised its stake in ImmuCell by 100.0% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 12,178 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of ImmuCell during the fourth quarter worth about $149,000. Northern Trust Corp increased its holdings in shares of ImmuCell by 51.0% during the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock valued at $229,000 after acquiring an additional 14,982 shares in the last quarter. Geode Capital Management LLC raised its position in shares of ImmuCell by 13.9% in the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock valued at $332,000 after purchasing an additional 7,878 shares during the last quarter. Finally, Dauntless Investment Group LLC acquired a new stake in ImmuCell in the 4th quarter worth approximately $676,000. Institutional investors and hedge funds own 13.47% of the company’s stock.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.